Cadence Pharmaceuticals, Inc.  

(Public, NASDAQ:CADX)   Watch this stock  
Find more results for CADX
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 1.25B
P/E     -
Div/yield     -
EPS -0.28
Shares 89.18M
Beta 1.27
Inst. own 84%
Mar 3, 2014
Cadence Pharmaceuticals, Inc. at Morgan Stanley Technology, Media & Telecom Conference
Feb 28, 2014
Q4 2013 Cadence Pharmaceuticals, Inc. Earnings Release
Feb 11, 2014
Mallinckrodt Plc Conference Call to discuss its Acquisition of Cadence Pharmaceuticals,Inc - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -11.66% -21.58%
Operating margin -8.49% -24.47%
EBITD margin - -23.09%
Return on average assets -18.90% -25.78%
Return on average equity -47.70% -58.76%
Employees 210 -
CDP Score - -


Suite 200, 12481 High Bluff Drive
United States - Map
+1-858-4361400 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cadence Pharmaceuticals, Inc. (Cadence) is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. In March 2014, Mallinckrodt Plc acquired Cadence Pharmaceuticals, Inc. In March 2014, Mallinckrodt Plc completed the acquisition of Cadence Pharmaceuticals.